title: Prevalence of unrecognized abnormal glucose tolerance in patients attending a hospital hypertension clinic.
abstract: BACKGROUND
  Diabetes mellitus (DM) and impaired glucose tolerance (IGT) are not uncommonly associated with hypertension. Fasting blood glucose level is still recognized as an indicator of DM.
  
  
  METHODS
  We studied 99 consecutive patients who were not known to be diabetic patients and with no cardiac history, who were attending our Hypertension Clinic for investigation and management of uncontrolled blood pressure (BP). Oral glucose tolerance test (GTT) was carried out and area under the curve for the GTT (AUC-glucose) was calculated. All patients underwent 24-h ambulatory BP monitoring.
  
  
  RESULTS
  The GTT was abnormal in 58 patients (58%), indicating IGT in 18, impaired fasting glucose in 16, and DM in 24. The fasting and 120-min glucose level and AUC-glucose in patients with DM on GTT was higher (P <.0001) than in those with IGT/IFG and in the latter was higher than those with normal GTT. Multiple regression analysis showed that abnormal GTT was independent of the following: level of clinic or ambulatory BP; presence or absence of nocturnal BP dip; cholesterol, sodium, and potassium levels; smoking history; alcohol intake; prior treatment for hypertension; and ethnicity. These results were also independent of antihypertensive medications taken. No significant difference was found in glucose level during GTT, AUC-glucose, or age among the groups of patients receiving diuretics only, those receiving diuretics and beta-blockers, and those not receiving any of these agents.
  
  
  CONCLUSIONS
  The prevalence of glucose abnormalities in hypertensive patients attending a hospital hypertension clinic is sufficiently high to warrant screening for DM and IGT, and fasting glucose levels are not accurate enough for this purpose. All patients attending such a clinic should undergo a GTT.
authors.affiliation: Cardiac Research Unit, Cardiology Department, Central Middlesex Hospital, London, United Kingdom. majeed.salmasi@nwlh.nhs.uk
authors.forename: Abdul-Majeed
authors.initials: AM
authors.lastname: Salmasi
authors.forename: Audrey
authors.initials: A
authors.lastname: Alimo
authors.forename: Mark
authors.initials: M
authors.lastname: Dancy
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D018660:Blood Pressure Monitoring, Ambulatory; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000453:epidemiology* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010044:Outpatient Clinics, Hospital; D015995:Prevalence; D013223:Statistics as Topic; D016896:Treatment Outcome; D014280:Triglycerides / Q000378:metabolism; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D000319:Adrenergic beta-Antagonists; D015415:Biomarkers; D001786:Blood Glucose; D014280:Triglycerides